SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    United Nations Office of Drugs and Crime (UNODC). World drug report 2009. United Nations publications, 314 p. Available at http://www.unodc.org/documents/wdr/WDR_2009/WDR2009_eng_web.pdf (last accessed 6 August 2010).
  • 2
    Beck F, Legleye S, Spilka S. Niveaux d'usage et profils des usagers en France en 2005. In: Costes JM, Cannabis, Données Essentielles, eds. Martineau H, Ades JE. Saint-Denis: Observatoire français des drogues et toxicomanies (OFDT), 2007; 209. Available at http://www.ofdt.fr/BDD/publications/docs/cdecomp.pdf (last accessed 6 August 2010).
  • 3
    Winstock AR, Ford C, Witton J. Assessment and management of cannabis use disorders in primary care. BMJ 2010; 340: c1571.Review.
  • 4
    [No authors listed]. Cannabis and the cardiovascular system. Br Med J 1978; 1: 4601.
  • 5
    Sterne J, Ducastaing C. [Arteritis caused by Cannabis indica]. Arch Mal Coeur Vaiss 1960; 53: 1437. French.
  • 6
    Mohan H, Sood GC. Conjugate deviation of the eyes after Cannabis indica intoxication. Br J Ophthalmol 1964; 48: 1601.
  • 7
    Charles R, Holt S, Kirkham N. Myocardial infarction and marijuana. Clin Toxicol 1979; 14: 4338.
  • 8
    International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). ICH topic E6 (R1): Guideline for good clinical practice (CPMP/ICH/135/95). London: European Medecines Agency, 1996.
  • 9
    Institut National de la Statistique et des Etudes Economiques (INSEE). 2009 [Internet]. Statistiques locales, chiffres clés sur un territoire [updated 01/12/2009]. INSEE. Available at http://www.insee.fr/fr/bases-de-donnees/default.asp?page=statistiques-locales.htm (last accessed 6 August 2010).
  • 10
    World Health Organization [Internet]. International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Version for 2007; c1994/2006 [update 05/04/2006]. World Health Organization. Available at: http://apps.who.int/classifications/apps/icd/icd10online/ (last accessed 6 August 2010).
  • 11
    Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 12559.
  • 12
    Wiholm BE, Olsson S, Moore N, Waller P. Spontaneous reporting systems outside the US. In: Pharmacoepidemiology, ed. Strom BL. 3rd edn. Chichester: Wiley, 2000; 17592.
  • 13
    WHO. International Monitoring of Adverse Reactions to Drugs: Adverse Reaction Terminology. Uppsala: WHO Collaborating Centre for International Drug Monitoring, 1992.
  • 14
    Beck F, Legleye S, Spilka S. Cannabis, cocaïne, ecstasy: entre expérimentation et usage régulier. In: Baromètre santé 2005. Attitudes et comportement de santé, ed. Cormand MF. Saint-Denis: Institut national de prévention et d'éducation pour la santé (INPES), Baromètres santé, 2007; 169221. Available at http://www.inpes.sante.fr/CFESBases/catalogue/pdf/1109.pdf (last accessed 6 August 2010).
  • 15
    Institut National de la Statistique et des Etudes Economiques (INSEE). 2008 [Internet]. Estimation de population par sexe et âge quinquennal, Années 1990–2007 [updated 05/2008]. INSEE. Available at: http://www.insee.fr/fr/themes/detail.asp?reg_id=99&ref_id=estim-pop (last accessed 6 August 2010).
  • 16
    Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet 2009; 374: 138391.
  • 17
    Aryana A, Williams MA. Marijuana as a trigger of cardiovascular events: speculation or scientific certainty? Int J Cardiol 2007; 118: 1414.
  • 18
    Aronow WS, Cassidy J. Effect of marihuana and placebo-marihuana smoking on angina pectoris. N Engl J Med 1974; 291: 657.
  • 19
    Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. Circulation 2001; 103: 28059.
  • 20
    Combemale P, Consort T, Denis-Thelis L, Estival JL, Dupin M, Kanitakis J. Cannabis arteritis. Br J Dermatol 2005; 152: 1669.
  • 21
    Bonnaud I, Giraudeau B, Julie V, Soulat L, Beaufils JM, Brock T, Goralski M, Perrotin D, les médecins référents membres du GEUC. [Epidemiology and management of stroke patients in emergency departments of the Centre region of France]. Rev Neurol 2005; 161: 3117. French.
  • 22
    Ducasse A. (Dir), Rapport annuel sur l'activité des structures d'urgence en Midi-Pyrénées 2008, Observatoire Régional des Urgences Midi-Pyrénées (ORU-MIP). 2009: 169p. Available at http://www.oru-mip.fr/docs/urg2008.pdf (last accessed 6 August 2010).
  • 23
    Tetrault JM, Crothers K, Moore BA, Mehra R, Concato J, Fiellin DA. Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review. Arch Intern Med 2007; 167: 2218.
  • 24
    Gilbert O, Mathieu D, Hanquet O, Lardinois I, Cornut P, Pierard P, Van Meerhaeghe A. [Hemoptysis in a young man]. Rev Mal Respir 2006; 23: 4716.
  • 25
    Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry 2001; 178: 1016.
  • 26
    Park B, McPartland JM, Glass M. Cannabis, cannabinoids and reproduction. Prostaglandins Leukot Essent Fatty Acids 2004; 70: 18997.
  • 27
    Steinberger EK, Ferencz C, Loffredo CA. Infants with single ventricle: a population-based epidemiological study. Teratology 2002; 65: 10615.
  • 28
    Delourme J, Delattre C, Godard P, Steenhouwer F, Just N. [Respiratory consequences of inhalation of adulterated cannabis]. Rev Mal Respir 2009; 26: 5526. French.
  • 29
    van der Hooft CS, Sturkenboom MC, van Grootheest K, Kingma HJ, Stricker BH. Adverse drug reaction-related hospitalisations: a nationwide study in The Netherlands. Drug Saf 2006; 29: 1618.
  • 30
    Patel H, Bell D, Molokhia M, Srishanmuganathan J, Patel M, Car J, Majeed A. Trends in hospital admissions for adverse drug reactions in England: analysis of national hospital episode statistics 1998–2005. BMC Clin Pharmacol 2007; 7: 9.